Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Multidisciplinary Management of Rare Head and Neck Tumors: The Importance...
share announcement

Multidisciplinary Management of Rare Head and Neck Tumors: The Importance of Knowing and Dealing with Them

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 461

Special Issue Editor

Dr. Francesco Perri

E-Mail Website
Guest Editor
Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, Via Mariano Semmola, 80131 Napoli, Italy
Interests: head and neck oncology; immune-therapy; targeted therapy; pain therapy; electrochemotherapy; cancer diagnostics; treatment tumors; cancer biology; cancer biomarkers; tumor biology cancer; cell biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Head and neck tumors represent about 7–8% of all malignancies, and nearly 90% of them have squamous histology. Excluding nonmelanoma skin cancer, the remaining 10% of head and neck carcinomas may arise from the salivary gland, nasopharynx (nonsquamous), and nasal cavity/paranasal sinuses (nonsquamous). Additionally, there are also rare tumors in the head and neck area different from those above, and given their particular rarity they could be defined as rate tumors of the head and neck (RTsHN). These may have different histologies and different embryonic derivations. The management of RTsHN is challenging since, often, no available guidelines are present.

In recent years, advancements in molecular profiling and genomic characterization have provided invaluable insights into the underlying biology of rare head and neck cancers, unravelling novel therapeutic targets and paving the way for precision medicine approaches; however, significant gaps persist in our understanding of these malignancies, hindering progress towards improved outcomes. Through a meticulous review of the existing literature, coupled with insights gleaned from clinical practice and translational research, we endeavor to elucidate the etiopathogenesis, clinical characteristics, diagnostic modalities, treatment strategies, and prognostic factors pertaining to these malignancies.

Dr. Francesco Perri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rare head and neck cancers
  • translational research
  • therapeutic targets

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 5882 KiB  
Article
Long-Term Outcomes of Esophageal Squamous Neoplasia with Muscularis Mucosa Involvement after Endoscopic Submucosal Dissection
by Chen-Huan Yu, Yueh-Hung Chou, Tze-Yu Shieh, Chao-Yu Liu, Jiann-Ming Wu, Chen-Hsi Hsieh, Tzong-Hsi Lee and Chen-Shuan Chung
Biomedicines 2024, 12(8), 1660; https://doi.org/10.3390/biomedicines12081660 - 25 Jul 2024
Viewed by 206
Abstract
Ambiguity exists over treatment and surveillance strategies after endoscopic submucosal dissection (ESD) for esophageal squamous cell neoplasia (ESCN) with unfavorable histologic features. This study investigated the long-term outcomes of ESD in high-risk ESCN patients. We retrospectively included early ESCN patients treated with ESD [...] Read more.
Ambiguity exists over treatment and surveillance strategies after endoscopic submucosal dissection (ESD) for esophageal squamous cell neoplasia (ESCN) with unfavorable histologic features. This study investigated the long-term outcomes of ESD in high-risk ESCN patients. We retrospectively included early ESCN patients treated with ESD at two medical centers in Taiwan between August 2010 and December 2023. Demographic, endoscopic and pathological data were collected. Among 146 patients (mean age 59.17 years) with 183 lesions, 73 (50%) had a history of head and neck cancer (HNC). En bloc and R0 resections were achieved in 100% and 95.6% of the lesions, respectively. The 5-year overall survival (OS), disease-specific survival (DSS) and local recurrence rates were 42.7%, 94.7% and 11%. R0 resections were significantly associated with recurrence in a univariate analysis (HR: 0.19, 95% CI: 0.06–0.66, p = 0.008). Alcohol abstinence was independently associated with lower recurrence (HR: 0.34, 95% CI: 0.16–0.73, p = 0.006). Patients with pT1a-MM (muscularis mucosa invasion) had comparable OS (p = 0.82), DSS (p = 0.617) and recurrence (p = 0.63) rates to those with pT1a-EP/LPM (epithelium/lamina propria invasion). The long-term outcomes of ESCN patients after ESD for expanded indications were satisfactory. ESD could be considered in selected ESCN patients involving the muscularis mucosa, notably among high-risk HNC patients. Full article
(This article belongs to the Special Issue Multidisciplinary Management of Rare Head and Neck Tumors: The Importance of Knowing and Dealing with Them)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop